We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Collagen Solutions Plc | LSE:COS | London | Ordinary Share | GB00B94T6Y14 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 6.625 | 6.25 | 7.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From May 2019 to May 2024
TIDMCOS
RNS Number : 1694T
Collagen Solutions PLC
13 November 2019
13 November 2019
Collagen Solutions plc
("Collagen Solutions" or the "Company")
Directorate Change
Collagen Solutions Plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that it has decided to streamline its Board of Directors by limiting the Executive Officers on the Board to only the CEO and CFO, reducing its size from eight members to six.
Lou Ruggiero, Chief Business Officer, and Tom Hyland, Chief Operating Officer, will resign from the Company Board of Directors. Mr. Ruggiero's role with the Company will remain unchanged. Mr. Hyland will transition to a Chief Technical Adviser role in a consulting capacity and the Company does not plan to backfill the Chief Operating Officer position.
Chris Brinsmead, Chairman of Collagen Solutions, commented: "As the Company is preparing for its next stage of growth the time is right to adjust to a slimmer, more efficient executive team and Board. The executive team is highly focused on upgrading our production capabilities, strengthening our technical excellence, and organising the Company around meeting the growing demand for biomaterials product supply, development and contract manufacturing. By streamlining the Board, this enables the executive team to focus on these critical activities, whilst ensuring effective and efficient governance and support of the Board."
Collagen Solutions Plc Jamal Rushdy, CEO Via Walbrook Hilary Spence, CFO Cenkos Securities Plc (Nominated Adviser and Broker) Giles Balleny (Corporate Finance) Tel: 0207 397 8900 Stephen Keys Walbrook PR Ltd Tel: 020 7933 8780 or collagen@walbrookpr.com Anna Dunphy Mob: 07876 741 001
About Collagen Solutions:
Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, tissue engineering, and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic(R). The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.
For more information go to: www.collagensolutions.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
BOALLFEELFLFLIA
(END) Dow Jones Newswires
November 13, 2019 02:01 ET (07:01 GMT)
1 Year Collagen Solutions Chart |
1 Month Collagen Solutions Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
